Norman Stockbridge, MD, PhD
Division Director, Division of Cardiology and Nephrology, FDA CDER
CDER division director who attended Dr. Szarfman's December 2020 meeting on new safety methodology and received her May 2021 analysis on undervalued myocardial infarction signals.
Timeline appearances (4)
- analysis
Szarfman organizes a virtual meeting on a new safety data mining methodology designed by DuMouchel.
- analysis
Szarfman shares DuMouchel's RGPS analysis showing 49 examples of extreme masking with senior FDA officials.
- analysis
Szarfman circulates analysis showing MGPS undervalued acute myocardial infarction signals for Pfizer and Moderna.
- publication
Szarfman receives clearance from Stockbridge to publish her paper on masking and RGPS.